Tag Archives: drug

Homeland Security Chief Speaks About Challenges Facing U.S., Global Cooperation

The United States is stronger and more secure than it was prior to 9/11, but threats from overseas remain and must be proactively managed, said Secretary of Homeland Security Janet Napolitano, who visited campus April 16 for a public talk sponsored by the UCLA Burkle Center for International Relations.

In a globalized world, international cooperation is the key to identifying those who intend to do harm, she said, adding that threats to the global supply chain, the activities of drug and human smuggling organizations, and the prevalence of cyber-criminals who attempt to steal information and intellectual property and disrupt critical networks are among the major challenges facing the Department of Homeland Security. (more…)

Read More

Freezing Technique Exposes Molecule-to-Molecule Attachments

Researchers at Yale University have developed a new way of exposing the atomic attachments that keep complex molecules in precise alignment. The new method could provide insight into the mechanics of a variety of molecular structures, potentially aiding efforts to manipulate them for drug discovery and other purposes.

“The method appears likely to become a central tool for the characterization of processes that depend on supramolecular associations,” said Mark Johnson, a Yale chemistry professor and the principal investigator of the technique, which is described in a paper published this month in the journal Science. Supramolecular associations are interactions taking place between molecules, rather than within them. (more…)

Read More

In Lab, Pannexin1 Restores Tight Binding of Cells Lost in Cancer

*By studying tumor cell behavior in a novel “scaffold-free” 3-D system, researchers have determined that the protein Pannexin1 may play an important biomechanical role in binding tissues together, an effect that is lost in cancerous cells.*

PROVIDENCE, R.I. [Brown University] — First there is the tumor and then there’s the horrible question of whether the cancerous cells will spread. Scientists increasingly believe that the structural properties of the tumor itself, such as how tightly the tumor cells are packed together, play a decisive role in the progression of the disease. In a new study, researchers show that the protein Pannexin1, known to have tumor-suppressive properties, plays an important role in keeping the cells within a tissue closely packed together, an effect that may be lost with cancer.

“In healthy tissues, the recently discovered protein Pannexin1 may be playing an important role in upholding the mechanical integrity of the tissue,” said first author and Brown University M.D./Ph.D. student Brian Bao. “When we develop cancer, we lose Pannexin1 and we lose this integrity.” (more…)

Read More

Researchers Uncover How New Melanoma Drug Accelerates Secondary Skin Cancers

Patients with metastatic melanoma taking the recently approved drug vemurafenib (marketed as Zelboraf) responded well to the twice-daily pill, but some of them developed a different, secondary skin cancer.

Now, researchers at UCLA’s Jonsson Comprehensive Cancer Center, working with investigators from the Institute of Cancer Research in London, Roche and Plexxikon, have elucidated the mechanism by which the drug excels at fighting melanoma but also allows for the development of skin squamous-cell carcinomas. (more…)

Read More

Ovarian Cancer Study Proves Drug Delays Disease Progression

*U of T, U.K. study focused on Avastin*

Treating ovarian cancer with the drug bevacizumab (“Avastin”) delays the disease and may also improve survival, according to an international clinical trial co-led by Drs. Amit Oza of the University of Toronto and Princess Margaret Hospital (PMH) and Timothy Perren of St James’s Institute of Oncology, Leeds, U.K.

The findings, published on Dec. 28 in the New England Journal of Medicine, report that the drug halted the cancer’s return for two months overall. However, for women with the highest risk disease, the delay was five to six months and in this group, the findings also indicate a strong trend to improved overall survival, which is being analysed until 2013. (more…)

Read More

Smokers with Mental Disorders, Drug and Alcohol Problems Need Doctors’ Help to Quit

Smokers who also have alcohol, drug and mental disorders would benefit greatly from smoking-cessation counseling from their primary care physicians and would be five times more successful at kicking the habit, a study by researchers at UCLA’s Jonsson Comprehensive Cancer Center has found.

Smokers with these co-morbid conditions make up about 40 percent of the smoking population, have a more difficult time quitting and represent a significant burden on the health care system. If their primary care physicians could help them to quit smoking, it would not only improve their health of patients but would reduce tobacco-related health care costs, said Dr. Michael Ong, an assistant professor of general internal medicine and health services research at the David Geffen School of Medicine at UCLA and a researcher with UCLA’s Jonsson Comprehensive Cancer Center. (more…)

Read More

Lab Studies Show Promise for New Multiple Sclerosis Treatment

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder. 

Watkins and her colleagues in CU-Boulder’s department of psychology and neuroscience discovered that a single injection of a compound called ATL313 — an anti-inflammatory drug being developed to treat chronic pain — stopped the progression of MS-caused paralysis in rats for weeks at a time.  (more…)

Read More

Made in IBM Labs: McKesson Taps IBM to Reduce Greenhouse Gas Emissions, Boost Pharmaceutical Supply Chain Efficiency

*Collaborative Research Project Uses Analytics Technology to Improve Effectiveness of North American Pharmaceutical Distribution Network*

ARMONK, N.Y. – 15 Nov 2010: McKesson Corporation and IBM are teaming on an initiative aimed at reducing carbon dioxide emissions and trimming drug distribution costs.  Working with IBM researchers and business consultants, North America’s largest distributor of prescription drugs is bringing a new level of intelligence to the pharmaceutical supply chain as well as its own business operations.   

McKesson supplies one-third of the prescription drugs used by hospitals and pharmacies in North America every day.  The company provides pharmaceuticals to more than 40,000 health locations in the U.S., ranging from hospitals and health systems to community pharmacies and national chain stores to the Department of Veterans Affairs.    (more…)

Read More